论文部分内容阅读
目的 :观察辛伐他汀和微粒化非诺贝特治疗原发性高脂血症病人降脂疗效及对 Apo A、Apo B的影响。方法 :30例原发性高脂血症患者随机被分为微粒化非诺贝特 (F,2 0 0 mg/日 )组和辛伐他汀 (S,5 mg/日 )组 ,进行自身交叉试验。结果 :治疗 4周后 ,两者降 TC、TG均有显著的疗效 ,但 S组以降低 TC和 Apo B为主 (分别为 2 0 .7%和 2 0 % ) ,F组以降 TG和升 HDL 为主 (分别为 49.7%和 2 9.5 % ) ,并有显著降尿酸作用。结论 :对于高脂血症患者应该根据其不同类型选择适当的降脂药
Objective: To observe the effects of simvastatin and micronized fenofibrate on lipid-lowering efficacy and Apo A and Apo B in patients with primary hyperlipidemia. Methods: Thirty patients with primary hyperlipidemia were randomized into groups of micronized fenofibrate (F, 200 mg daily) and simvastatin (S, 5 mg daily) test. Results: After 4 weeks of treatment, both TC and TG decreased significantly, but TC and Apo B were mainly decreased in S group (20.7% and 20% respectively), while F and TG decreased HDL (49.7% and 29.5%, respectively), with a significant reduction in uric acid. Conclusion: Patients with hyperlipidemia should choose appropriate lipid-lowering drugs according to their different types